Frankfurt - Delayed Quote EUR

Coherus BioSciences, Inc. (8C5.F)

0.9456

-0.0739

(-7.25%)

As of 8:03:06 AM GMT+1. Market Open.

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00

GlobeNewswire 18 hours ago

CHRS
With 59% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns

Key Insights Given the large stake in the stock by institutions, Coherus BioSciences' stock price might be vulnerable...

Simply Wall St. 4 days ago

CHRS
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on CHRS. Coherus BioSciences, Inc. (CHRS)’s share was trading at $1.11 as of Feb 11th. Coherus BioSciences (CHRS) is currently facing a pivotal moment, shifting from a potentially undervalued turnaround opportunity to […]

Insider Monkey 19 days ago

CHRS
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor activity was observed across both viral and non-viral etiologies – – Data support continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC – - Randomized Phase 2 trial evaluating casdozokitug/bevacizumab/toripalimab now open for enrollment – REDWOOD CITY, Calif., Jan. 22, 2025 (GLO

GlobeNewswire last month

CHRS
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-antagonistic antibody, in combination with atezolizumab (atezo) and bevaciz

GlobeNewswire 2 months ago

CHRS
Sector Update: Health Care Stocks Decline Premarket Tuesday

Health care stocks were declining premarket Tuesday, with The Health Care Select Sector SPDR Fund (X

PREMIUM
MT Newswires 2 months ago

CHRS
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody - - Post-closing proceeds to repay the entirety of the company’s $230 million convertib

GlobeNewswire 2 months ago

CHRS
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M

The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to $558 million.

BioPharma Dive 2 months ago

CHRS
Q3 2024 Coherus BioSciences Inc Earnings Call

Q3 2024 Coherus BioSciences Inc Earnings Call

Thomson Reuters StreetEvents 3 months ago

CHRS
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Coherus BioSciences Inc (CHRS) reports significant revenue growth and market share gains, despite facing supply interruptions impacting future sales projections.

GuruFocus.com 3 months ago

CHRS
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 90% and 24.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

CHRS
Coherus BioSciences: Q3 Earnings Snapshot

REDWOOD CITY, Calif. AP) — Coherus BioSciences Inc. CHRS) on Wednesday reported a loss of $10.8 million in its third quarter.

Associated Press Finance 3 months ago

CHRS
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract manufacturing organization – – LOQTORZI® launch progressing to plan, revenues increase 50% quarter-over-quarter – – Innovative immuno-oncology pipeline advancing to proof-of-concept studies in combination with toripalimab – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Nov. 06, 202

GlobeNewswire 3 months ago

CHRS
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the c

GlobeNewswire 4 months ago

CHRS
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Coherus BioSciences Inc (CHRS) reports a 10% increase in total revenue and significant progress in its oncology portfolio, despite ongoing challenges.

GuruFocus.com 4 months ago

CHRS
Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Coherus BioSciences, Inc. (NASDAQ:CHRS) stands against the other Worst 52-Week Low Stocks. The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the […]

Insider Monkey 5 months ago

CHRS

^GSPC
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Coherus BioSciences, Inc. (NASDAQ:CHRS) stands against the other worst 52-week low stocks to buy now according to short sellers. The U.S. Federal Reserve conducting a […]

Insider Monkey 5 months ago

CHRS

^GSPC
Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses

Key Insights Institutions' substantial holdings in Coherus BioSciences implies that they have significant influence...

Simply Wall St. 5 months ago

CHRS
Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations

Coherus BioSciences ( NASDAQ:CHRS ) Second Quarter 2024 Results Key Financial Results Revenue: US$65.0m (up 11% from 2Q...

Simply Wall St. 6 months ago

CHRS
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 33.33% and 13.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 months ago

CHRS

Performance Overview

Return	8C5.F	S&P 500
YTD	-32.75%	-0.54%
1-Year	-56.72%	+14.01%
3-Year	-85.02%	+35.13%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Coherus BioSciences, Inc. (8C5.F)

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

With 59% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Sector Update: Health Care Stocks Decline Premarket Tuesday

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M

Q3 2024 Coherus BioSciences Inc Earnings Call

Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates

Coherus BioSciences: Q3 Earnings Snapshot

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges

Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses

Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Performance Overview